Biodesix plans a CT-and-blood lung test. What exists today?
A new lung-nodule test is in development, with first data promised for December. We compare its proposed workflow with OpenOnco’s current role.
Written retrospectively and published on October 22, 2026.
A company announcement is not independent evidence of clinical benefit. This comparison is informational, not medical advice. This article does not replace a doctor.
On 19 October, Biodesix announced a digital diagnostic in development with Vanderbilt: it would extract features from CT images of lung nodules and complement its existing Nodify Lung blood tests. The company expects first performance data on 3 December 2026 and commercial availability in 2028. Its announced prospective STRATIFY study is intended to collect matched imaging, blood-marker and outcome data. These are plans, not published validation of the new combined test. No sensitivity, specificity or patient-outcome result for that test was supplied in the announcement.
The products answer different questions. Biodesix aims to estimate whether a lung nodule is malignant from images and blood; OpenOnco does not interpret scans or blood samples. Its free, MIT-licensed, public rules and cited sources help draft oncology discussion paths after clinical facts are known. Clinical content in OpenOnco remains under review. As checked on 22 October, Biodesix described the planned test but did not publish its price or source-code licence. No direct study compares the tools, and neither announcement justifies a claim of better survival. A clinician must interpret findings and choose care; this article is not a substitute for a physician.
Comments
Threads are public and indexed — please keep personal medical data out of them. Found a clinical error? Open an issue instead.
Comments are not switched on yet — the backend still needs to be configured.